KRAS Codon 61 Mutation Detection Test
Comprehensive Introduction to KRAS Mutation Testing
The KRAS Codon 61 Mutation Detection Test represents a cutting-edge advancement in precision oncology, offering critical insights into cancer genetics that directly impact treatment decisions. This specialized molecular diagnostic examination focuses on identifying specific genetic alterations within the KRAS gene at the crucial codon 61 position. As one of the most frequently mutated genes in human cancers, KRAS mutations play a pivotal role in cancer development, progression, and treatment response.
Understanding KRAS mutations is essential because they activate signaling pathways that drive uncontrolled cell growth and division. The codon 61 location is particularly significant as mutations at this site can confer resistance to certain targeted therapies while potentially indicating sensitivity to others. This test provides oncologists with actionable genetic information that transforms cancer care from generalized treatment approaches to highly personalized therapeutic strategies.
What the KRAS Codon 61 Test Measures and Detects
This sophisticated genetic analysis specifically targets and identifies mutations occurring at codon 61 of the KRAS gene. The test utilizes advanced Polymerase Chain Reaction (PCR) technology to examine tumor tissue samples for the presence of specific genetic alterations including:
- Point mutations at codon 61 position
- Specific amino acid substitutions (Q61H, Q61K, Q61L, Q61R)
- Genetic variations affecting KRAS protein function
- Mutations that impact downstream signaling pathways
The detection of these mutations provides crucial information about the molecular characteristics of the tumor, enabling healthcare providers to make informed decisions regarding targeted therapy selection and treatment planning.
Who Should Consider KRAS Codon 61 Mutation Testing
This genetic test is particularly valuable for patients diagnosed with specific cancer types where KRAS mutations commonly occur and influence treatment outcomes. Individuals who may benefit from this testing include:
- Patients diagnosed with colorectal cancer considering anti-EGFR therapy
- Individuals with pancreatic adenocarcinoma for prognostic assessment
- Non-small cell lung cancer patients evaluating treatment options
- Those with metastatic cancer requiring targeted therapy selection
- Patients with treatment-resistant cancers needing alternative approaches
- Individuals participating in clinical trials requiring genetic profiling
Significant Benefits of KRAS Mutation Detection
Undergoing KRAS Codon 61 Mutation Detection provides numerous advantages for cancer patients and their healthcare teams:
- Personalized Treatment Planning: Identifies whether patients are candidates for specific targeted therapies
- Avoidance of Ineffective Treatments: Prevents administration of medications unlikely to provide benefit
- Improved Treatment Outcomes: Enables selection of therapies with higher likelihood of success
- Prognostic Information: Provides insights into disease behavior and potential progression
- Clinical Trial Eligibility: Helps identify appropriate targeted therapy trials
- Cost-Effective Care: Reduces healthcare costs by avoiding ineffective treatments
Understanding Your Test Results
Your KRAS Codon 61 Mutation Detection results will be carefully interpreted by our molecular pathology experts and provided in a comprehensive report. The interpretation typically includes:
- Mutation Detected: Indicates the presence of a KRAS codon 61 mutation, which may suggest resistance to certain EGFR-targeted therapies but potential sensitivity to alternative treatments
- No Mutation Detected: Suggests the tumor is wild-type at codon 61, potentially making patients candidates for EGFR inhibitor therapies
- Specific Mutation Identified: Details the exact genetic alteration found, providing precise information for treatment decision-making
It’s essential to discuss your results with your oncologist, who will interpret them in the context of your specific cancer type, stage, and overall treatment plan. Our genetic counselors are available to help you understand the implications of your results.
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $212 |
| Regular Price | $376 |
| Turnaround Time | 15 days (sample submitted by 11 am) |
| Sample Type | Fresh tissue in normal saline OR formalin fixed paraffin embedded block |
Nationwide Testing Availability
GGC DNA provides comprehensive KRAS Codon 61 Mutation Detection testing services across the United States. We have established testing facilities and collection centers in all major metropolitan areas including:
- New York City and surrounding regions
- Los Angeles and Southern California
- Chicago and the Midwest
- Houston and Texas metropolitan areas
- Phoenix and Arizona regions
- Philadelphia and the Northeast
- All other major US cities and regions
Our network ensures that patients nationwide have access to this critical genetic testing without the need for extensive travel. Each facility maintains the same high standards of quality, accuracy, and patient care.
Take the Next Step in Your Cancer Care Journey
Don’t leave your treatment decisions to chance. The KRAS Codon 61 Mutation Detection Test provides the genetic intelligence needed to make informed choices about your cancer therapy. With our discounted price of $212 USD and comprehensive nationwide availability, there’s no reason to delay this essential testing.
Call us today at +1(267) 388-9828 to schedule your test or speak with our genetic counseling team. Our specialists are ready to answer your questions, explain the testing process, and help you take control of your cancer treatment journey with confidence and clarity.
Early genetic testing can make a significant difference in treatment outcomes. Contact GGC DNA now to book your KRAS Codon 61 Mutation Detection Test and move forward with precision medicine tailored to your unique genetic profile.
